NWBO News Alert Northwest Biotherapeutics (NWBO) 5.58 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Northwest Biotherapeutics (NWBO) 5.58 $NWBO

Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...
at The Street - Mon Dec 15, 10:49AM CST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
NWBO: 5.58 (+0.04), DNDN: 0.13 (-0.02), RTRX: 12.92 (+0.19), CYTR: 2.58 (+0.03), RPRX: 8.88 (+0.24), GALE: 1.49 (-0.02), AEGR: 21.59 (-0.27)

This Illegal Drug Could Be the Answer to Fighting Brain Cancer
Sean Williams, The Motley Fool - Motley Fool - Sun Dec 14, 10:41AM CST
Source: National Cancer Institute via Wikimedia Commons. There's pretty much nothing scarier than being told you have cancer. Although I've personally never been given this dreaded diagnosis, I was there by my mother's side when she was told in...
NWBO: 5.58 (+0.04)

NW BIO RECAPS 2014 PROGRESS, PROVIDES DCVAX-DIRECT TRIAL UPDATE AT OPPENHEIMER'S 25TH ANNUAL HEALTHCARE CONFERENCE
PR Newswire - Thu Dec 11, 10:59AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that NW Bio's CEO, Linda Powers, recapped the substantial progress made by the Company during 2014 in a presentation at Oppenheimer's 25th Annual Healthcare Conference in New York City.
NWBO: 5.58 (+0.04)

Northwest Biotherapeutics: An Analysis Of What We Know About DCVax Direct
Smith On Stocks - at Seeking Alpha - Mon Dec 01, 5:23AM CST

NWBO: 5.58 (+0.04), KITE: 51.96 (+0.45)

Commit To Buy Northwest Biotherapeutics At $3, Earn 25% Using Options
StockOptionsChannel.com - Wed Nov 26, 10:34AM CST
Investors considering a purchase of Northwest Biotherapeutics Inc stock, but cautious about paying the going market price of $5.16/share, might benefit from considering selling puts among the alternative strategies at their disposal. One...
NWBO: 5.58 (+0.04)

Northwest Biotherapeutics' DCVax-L: A Reimbursement Perspective
Ryan Pawell - at Seeking Alpha - Sun Nov 23, 3:41AM CST

NWBO: 5.58 (+0.04), DNDN: 0.13 (-0.02)

Update: Northwest Bio Benefits From Two Financings, Woodford Makes Encouraging Investment
Trevor Lowenthal - at Seeking Alpha - Fri Nov 21, 7:16AM CST

NWBO: 5.58 (+0.04)

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind
at The Street - Fri Nov 21, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
NWBO: 5.58 (+0.04), CLDX: 17.08 (-0.18), MNKD: 5.68 (+0.18), PBYI: 189.96 (+0.12)

Northwest Biotherapeutics posts 3Q loss
Automated Insights - Thu Nov 20, 5:51PM CST
BETHESDA, Md. (AP) _ Northwest Biotherapeutics Inc. (NWBO) on Thursday reported a loss of $21 million in its third quarter.
NWBO: 5.58 (+0.04)

Northwest Biotherapeutics: Capital Raise Of $35 Million Could Be A Positive Catalyst For The Stock
Smith On Stocks - Seeking Alpha - Thu Nov 20, 10:21AM CST
$35 Million Capital Raise Strengthens Balance Sheet Northwest Biotherapeutics (NASDAQ: NWBO ) announced after the market close on November 19th that it had completed a deal with the United Kingdom money manager Woodford Equity Income Fund to raise...
NWBO: 5.58 (+0.04)

NW BIO ANNOUNCES FINANCINGS TOTALING $35 MILLION TO EXPAND AND ACCELERATE DCVAX®-L AND DCVAX®-DIRECT PROGRAMS
PR Newswire - Wed Nov 19, 2:20PM CST
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today two financings totaling $35 million. The financings include a $25 million equity investment by UK based C.F. Woodford Equity Income Fund ("Woodford" , and a $10 million mortgage on the Company's recently acquired UK facility.
NWBO: 5.58 (+0.04)

Celldex Therapeutics To Enter Talks With FDA
Steven Giardino - Seeking Alpha - Tue Nov 18, 9:26AM CST
On Friday, Celldex Therapeutics (NASDAQ: CLDX ) announced results from a recently near completed Ph II trial testing Rindopepimut in recurrent glioblastoma ((rGBM)). The 72 patient, randomized, placebo controlled study (gold standard of trial design)...
NWBO: 5.58 (+0.04), CLDX: 17.08 (-0.18), SRPT: 13.88 (+0.47)

Product and Pipeline Analysis of the Global Vaccines Market
M2 - Tue Nov 11, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/4nt5s9/product_and) has announced the addition of the "Product and Pipeline Analysis of the Global Vaccines Market " report to their offering. Vaccines represent a class of biologics that are administered to prevent infectious diseases to reduce mortality and morbidity. It is estimated that the introduction of vaccines has reduced the incidence of various diseases by greater than 90%. This study examines the global vaccines market, including marketed products and products under clinical development. It also presents an overview of the value chain and regulatory environment, and offers profiles of key marketed and pipeline products. The market is segmented into infectious disease vaccines, cancer vaccines, allergy vaccines, and others (e.g., vaccines for physiological disorders such as diabetes and Alzheimer's disease). The base year is 2013. Key Findings:Vaccines are a class of biologics administered to prevent infectious diseases and reduce mortality and morbidity. - Vaccines are now available for prevention of about infectious diseases. - Coupled with powerful techniques such as polymerase chain reaction (PCR), mass spectrometry, and next-generation sequencing, the vaccine industry experienced a paradigm shift resulting in innovation and engineering of novel vaccines such as dendritic cell, DNA, and synthetic. - Infectious disease vaccines-particularly viral vaccines-represent the largest share in terms of products under clinical trial. There is an increased focus on developing vaccines with alternative delivery routes, such as oral and intranasal, to effectively replace the conventional injection method of administration. - One of the hallmarks of vaccine development is the improved understanding of the immune system. As a result, developers are pursuing vaccines for physiological diseases. - Developers also are researching vaccines for emerging infectious diseases such as respiratory syncytial virus (RSV), norovirus, human immunodeficiency virus (HIV), Epstein-Barr, malaria, and Leishmaniasis. - The United States, Europe, and Japan represent the largest markets for vaccine manufacturers; however, with increasing healthcare spending and awareness, emerging regions represent the fastest-growing and attractive markets. Key Topics Covered: 1. Executive Summary 2. Methodology and Scope 3. Introduction 4. Global Regulatory Oversight 5. Competitive Landscape 6. Competitive Landscape-Bacterial Vaccines 7. Competitive Landscape-Viral Vaccines 8. Competitive Landscape-Parasitic Vaccines 9. Competitive Landscape-Cancer Vaccines 10. Competitive Landscape-Allergy Vaccines 11. Competitive Landscape-Other Vaccines 12. Bacterial Vaccine Product Dashboard 13. Viral Vaccine Product Dashboard 14. Parasitic Vaccine Product Dashboard 15. Cancer Vaccine Product Dashboard 16. Allergy Vaccine Product Dashboard 17. Other Vaccine Products Dashboard 18. Timeline of Key Events 19. Conclusions Companies Mentioned - AFFiRiS - Archivel Farma - Biondvax - Bionor Pharma - Dendreon - GSK - Greer Laboratories - Immunitor - Inovio - Merck & Co - Nabi - Northwest Biotherapeutics - Novartis - PaxVax - Pfizer - Sanofi - Vaccinogen For more information visit http://www.researchandmarkets.com/research/4n...roduct_and
NWBO: 5.58 (+0.04), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)

NW BIO MAKING A JOINT POSTER PRESENTATION ON ITS DCVAX-DIRECT TRIAL AT THE 29TH ANNUAL SITC MEETING
PR Newswire - Fri Nov 07, 8:15AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it will be making a joint poster presentation relating to its DCVax-Direct Phase I/II Trial for inoperable solid tumor cancers at the 29th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
NWBO: 5.58 (+0.04)

NWBO: DCVax-Direct Validation And Updated DCVax-L Ph III Modeling
Steven Giardino - at Seeking Alpha - Thu Nov 06, 3:15PM CST

NWBO: 5.58 (+0.04), CLDX: 17.08 (-0.18)

The most undervalued, yet comprehensive cancer immunotherapy in development?
ACCESSWIRE - Mon Nov 03, 7:03AM CST
Los Angeles, CA / ACCESSWIRE / November 3, 2014 / The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
INO: 9.11 (-0.09), NWBO: 5.58 (+0.04), DNDN: 0.13 (-0.02), GALE: 1.49 (-0.02)

The Time Is Now For Northwest Biotherapeutics
Steven Giardino - Seeking Alpha - Wed Oct 29, 2:16PM CDT
Northwest Biotherapeutics (NASDAQ: NWBO ) has achieved a number of significant milestones over the past year while seeing its share price rise consistently on an upward trend, until somewhat recently. It may seem at first that the Company either...
NWBO: 5.58 (+0.04), PCYC: 121.84 (+1.15), JAZZ: 165.33 (+1.83), ICPT: 151.49 (+5.85), AAPL: 112.01 (-0.53)

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Northwest Biotherapeutics, Inc.
PR Newswire - Tue Oct 28, 1:41PM CDT
Levi & Korsinsky, LLP is investigating Northwest Biotherapeutics, Inc. ("Northwest Bio" or the "Company" (NasdaqCM: NWBO) in connection with possible breaches of federal securities laws. The investigation regards concerns that the Company made misleading statements regarding its clinical trial for DC-Vax Direct, its experimental cancer vaccine.
NWBO: 5.58 (+0.04)

Washington Post’s Pearlstein Didn't Intend to Disparage TheStreet’s Integrity
at The Street - Tue Oct 28, 1:32PM CDT
Steven Pearlstein, columnist for the Washington Post, says he never meant to disparage TheStreet's editorial standards in his Sept. 27 column examining TheStreet's Northwest Bio coverage.
TST: 2.46 (+0.03), NWBO: 5.58 (+0.04)

NORTHWEST BIOTHERAPEUTICS INC. ALERT -- Andrews & Springer LLC is Investigating Northwest Biotherapeutics Inc. for Potential Securities Fraud
GlobeNewswire - Mon Oct 20, 7:01AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities fraud claims against Northwest Biotherapeutics Inc. ("NWBO" or the "Company" .
NWBO: 5.58 (+0.04)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 95

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
ADFW 2026 Builds a Bigger Stage for Global Capital

Updated Category News Views 46

Abu Dhabi is not merely booking conference rooms this December; it is assembling a very deliberate display of financial muscle. Abu Dhabi Finance Week runs from 7 to 10 December 2026, and ADGM says its fifth edition will carry its largest-ever programme of partner-led activity. That is a promotional claim, sure, but the partner list is substantial enough that investors...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 97

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 99

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 60

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 57

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading

Top 5 Most Recently Viewed Articles

CHITA LIVING Showcases Stylish Furniture at Nashville Event

Updated Category News Views 333

CHITA LIVING Celebrates Style and Comfort at Nashville Event HOUSTON, Oct. 28, 2024 -- CHITA LIVING, a distinctive furniture company renowned for its stylish and inviting designs, is thrilled to be a part of Modern Luxury Nashville's exciting Announcement Party, happening soon at Diamond Creek Farms. This event showcases the perfect blend of comfort and elegance, a true...

Continue Reading
Buffy Payne Joins LifeKnight as Chief Security Officer

Updated Category News Views 236

Buffy Payne Joins LifeKnight as Chief Security Officer Expanding Global Safety Innovation Through AI-Driven Detection and Direction LifeKnight, Inc., a leader in AI-powered safety and health monitoring technology, has appointed Buffy Payne as Chief Security Officer (CSO). Bringing over three decades of experience in corporate security and crisis management, her role...

Continue Reading
Host Hotels & Resorts Achieves Remarkable Sustainability Milestone

Updated Category News Views 187

Host Hotels & Resorts Recognized for Sustainability Efforts Host Hotels & Resorts, Inc. (NASDAQ: HST), a leading name in the lodging real estate investment trust (REIT) sector, has made headlines once again. The company proudly announced its inclusion in the Dow Jones Sustainability World Index for the sixth year in a row, solidifying its reputation as a global...

Continue Reading
Toll Brothers Unveils New Luxury Community at The Pinehills

Updated Category News Views 220

Luxury Living in The Pinehills Community In a significant development for homebuyers, Toll Brothers, Inc. (NYSE:TOL), recognized as the leading builder of luxury homes in the nation, is excited to announce the opening of the Broadleaf community at The Pinehills. This luxurious community, designed with the discerning homeowner in mind, offers breathtaking new construction...

Continue Reading
Watts Water Technologies Faces Challenges but Sees Potential Growth

Updated Category News Views 330

Watts Water Technologies Reports Third Quarter Earnings Watts Water Technologies, Inc. (NYSE: WTS), a leader in providing water solutions globally, has announced its third-quarter results, marked by a blend of challenges and prospects for strategic advancements. CEO Bob Pagano, alongside CFO Shashank Patel and Senior VP Diane McClintock, discussed the company’s mixed...

Continue Reading